SCHEMBL24650804

SCHEMBL24650804

COc1cc2c(c(C(=O)O)c1)CC(N)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
ADRA1A P35348 1/20 0.39
KDM4E B2RXH2 3/20 0.37
CDC25B P30305 1/20 0.37
ACHE P22303 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
POLB P06746 1/20 0.36
KYAT1 Q16773 1/20 0.36
KYAT3 Q6YP21 1/20 0.36
AADAT Q8N5Z0 1/20 0.36
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
DYRK1A Q13627 1/20 0.34
FYN P06241 1/20 0.34
ALDH1A1 P00352 2/20 0.34
GABRR1 P24046 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24650781 0.87 KDM4E (0.40) DRD2DRD3ADRA1AKDM4EACHE
SCHEMBL24650807 0.84 AKR1C4 (0.37) SMN1; SMN2KDM4EACHECA1CA2
SCHEMBL24650874 0.82 HPGD (0.42) DRD2DRD3SMN1; SMN2KDM4ECDC25B
SCHEMBL24650879 0.78 KDM4E (0.46) DRD2DRD3ADRA1AKDM4EACHE
SCHEMBL24650802 0.78 FYN (0.42) DRD2DRD3KDM4ECDC25BCA1
SCHEMBL24651156 0.75 LMNA (0.43) DRD2DRD3ADRA1AACHECA1
SCHEMBL24650895 0.74 DRD2 (0.38) DRD2DRD3ADRA1AKDM4EACHE
SCHEMBL24650362 0.73 KDM4E (0.47) ADRA1AKDM4ECA1CA2FYN
SCHEMBL7681591 0.73 CXCR5 (0.48) SMN1; SMN2KDM4ECDC25BPOLBAKR1C3
SCHEMBL24650371 0.73 CA12 (0.49) DRD2DRD3ADRA1ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022238507-A1 THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS AWAKN LS EUROPE HOLDINGS LIMITED (IE) 2022-11-17 WO disclosed